[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL113844A - N-(alpha-ETHYLBENZYL)-3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE AND ITS USE IN THE PREPARATION OF MEDICAMENTS - Google Patents

N-(alpha-ETHYLBENZYL)-3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE AND ITS USE IN THE PREPARATION OF MEDICAMENTS

Info

Publication number
IL113844A
IL113844A IL11384495A IL11384495A IL113844A IL 113844 A IL113844 A IL 113844A IL 11384495 A IL11384495 A IL 11384495A IL 11384495 A IL11384495 A IL 11384495A IL 113844 A IL113844 A IL 113844A
Authority
IL
Israel
Prior art keywords
phenylquinoline
ethylbenzyl
carboxamide
medicaments
alpha
Prior art date
Application number
IL11384495A
Other languages
English (en)
Other versions
IL113844A0 (en
Original Assignee
Smithkline Beecham Farma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT94MI001099A external-priority patent/ITMI941099A1/it
Priority claimed from IT95MI000494 external-priority patent/IT1293558B1/it
Application filed by Smithkline Beecham Farma filed Critical Smithkline Beecham Farma
Publication of IL113844A0 publication Critical patent/IL113844A0/xx
Priority to IL12680698A priority Critical patent/IL126806A0/xx
Priority to IL13930100A priority patent/IL139301A0/xx
Publication of IL113844A publication Critical patent/IL113844A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Ceramic Engineering (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
IL11384495A 1994-05-27 1995-05-25 N-(alpha-ETHYLBENZYL)-3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE AND ITS USE IN THE PREPARATION OF MEDICAMENTS IL113844A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL12680698A IL126806A0 (en) 1994-05-27 1998-10-29 Quinoline derivatives
IL13930100A IL139301A0 (en) 1994-05-27 2000-10-26 Quinoline derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT94MI001099A ITMI941099A1 (it) 1994-05-27 1994-05-27 Derivati chinolinici
IT95MI000494 IT1293558B1 (it) 1995-03-14 1995-03-14 Derivati chinolinici

Publications (2)

Publication Number Publication Date
IL113844A0 IL113844A0 (en) 1995-08-31
IL113844A true IL113844A (en) 2005-05-17

Family

ID=26331143

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11384495A IL113844A (en) 1994-05-27 1995-05-25 N-(alpha-ETHYLBENZYL)-3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE AND ITS USE IN THE PREPARATION OF MEDICAMENTS

Country Status (35)

Country Link
US (5) US6608083B1 (ro)
EP (2) EP0804419B1 (ro)
JP (5) JP3664492B2 (ro)
KR (1) KR100316571B1 (ro)
CN (3) CN1092642C (ro)
AP (1) AP578A (ro)
AR (1) AR037069A2 (ro)
AT (2) ATE273959T1 (ro)
AU (1) AU699319B2 (ro)
BG (2) BG64004B1 (ro)
BR (1) BR9507788A (ro)
CA (1) CA2191352C (ro)
CZ (1) CZ291476B6 (ro)
DE (2) DE69531458T2 (ro)
DK (1) DK0804419T3 (ro)
DZ (1) DZ1889A1 (ro)
ES (2) ES2204952T3 (ro)
FI (2) FI115052B (ro)
HK (2) HK1003884A1 (ro)
HU (1) HU226535B1 (ro)
IL (1) IL113844A (ro)
MA (1) MA23560A1 (ro)
MX (1) MX9605903A (ro)
MY (1) MY129596A (ro)
NO (2) NO307783B1 (ro)
NZ (1) NZ287442A (ro)
OA (1) OA10592A (ro)
PL (2) PL186075B1 (ro)
PT (2) PT940391E (ro)
RO (1) RO114445B1 (ro)
SA (1) SA95160290B1 (ro)
SK (2) SK282721B6 (ro)
TW (2) TW427977B (ro)
UA (1) UA51623C2 (ro)
WO (1) WO1995032948A1 (ro)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO114445B1 (ro) 1994-05-27 1999-04-30 Smithkline Beecham S.P.A. Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
US6277862B1 (en) * 1995-11-24 2001-08-21 Smithkline Beecham S.P.A. Quinoline derivatives
GB9524137D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AU757836B2 (en) * 1995-11-24 2003-03-06 Smithkline Beecham Spa Quinoline derivatives
ES2222576T3 (es) * 1997-03-14 2005-02-01 Smithkline Beecham Corporation Nueva quinolina- y naftalenocarboxamidas, composiciones farmaceuticas y procedimientos que inhiben el calpain.
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20010012846A1 (en) * 1997-05-23 2001-08-09 Glardina Giuseppe Arnaldo Maria Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists
DE69816290T2 (de) * 1997-05-23 2004-05-27 Glaxosmithkline S.P.A. Chinolin-4-carboxamidderivate als nk-2 und nk-3 rezeptor antagonisten
EP1652840A3 (en) * 1997-09-17 2006-05-17 Smithkline Beecham Corporation (-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
AP1201A (en) * 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
TR200101412T2 (tr) * 1998-11-20 2001-10-22 Smithkline Beecham S.P.A. Yeni bileşikler.
GB9825554D0 (en) 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US6780875B2 (en) * 1998-11-20 2004-08-24 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
DE60018707T2 (de) * 1999-01-25 2006-02-09 Smithkline Beecham Corp. Anti-androgene und verfahren zur behandlung von krankheiten
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
CA2368455A1 (en) 1999-03-29 2000-10-05 Neurogen Corporation 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
WO2002013825A1 (en) * 2000-08-11 2002-02-21 Smithkline Beecham P.L.C. Novel pharmaceutical use of quinnoline derivatives
GB0028964D0 (en) * 2000-11-28 2001-01-10 Smithkline Beecham Spa Novel compounds
US6540733B2 (en) * 2000-12-29 2003-04-01 Corazon Technologies, Inc. Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
JP2004525184A (ja) * 2001-04-11 2004-08-19 グラクソスミスクライン・ソシエタ・ペル・アチオニ Ｎｋ−３およびｎｋ−２受容体アンタゴニストとしての３−置換キノリン−４−カルボキサミド誘導体
US20040152727A1 (en) * 2001-05-18 2004-08-05 Hay Douglas William Pierre Novel use
AU2003244080A1 (en) * 2002-06-26 2004-01-19 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
GB0228288D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0228287D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
RU2362780C2 (ru) 2003-12-22 2009-07-27 Глаксо Груп Лимитед Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний
KR100799802B1 (ko) 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
EP1729751A1 (en) * 2004-03-25 2006-12-13 Smithkline Beecham Corporation Use of an nk3 antagonist for the treatment of bipolar disorders
ES2301003T3 (es) * 2004-03-30 2008-06-16 Smithkline Beecham Corporation Composiciones farmaceuticas secadas por atomizacion.
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
NZ587547A (en) 2004-06-24 2012-09-28 Vertex Pharma Modulators of ATP-Binding Cassette Transporters
GB0417559D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0417560D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0425076D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425075D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
WO2006130080A2 (en) * 2005-06-03 2006-12-07 Astrazeneca Ab Quinoline derivatives as nk3 anatgonists
JP2008546767A (ja) * 2005-06-23 2008-12-25 アストラゼネカ・アクチエボラーグ Ｎｋ３受容体のモジュレーターとしてのキノリン３−スルホン酸エステル
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
EP1919871A4 (en) * 2005-08-02 2010-08-18 Glaxosmithkline Llc PROCESS FOR SYNTHESIS OF CHINOLINE DERIVATIVES
US20080200504A1 (en) * 2005-08-11 2008-08-21 Astrazeneca Ab Amide Alkyl Pyridiyl Quinolines as Nk3 Receptor Modulators
WO2007018469A1 (en) * 2005-08-11 2007-02-15 Astrazeneca Ab Oxopyridyl quinoline amides as nk3 receptor modulators
AR057130A1 (es) * 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
US20080234269A1 (en) * 2005-09-21 2008-09-25 Astrazeneca Ab N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
JP2009521468A (ja) * 2005-12-24 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体
HUE032813T2 (en) 2005-12-28 2017-11-28 Vertex Pharma Solid forms of N- [2,4-bis (1,1-dimethyl ethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
EP1981882A4 (en) * 2006-01-27 2009-11-18 Astrazeneca Ab QUINOLINES SUBSTITUTED BY AN AMIDE
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
ES2388454T3 (es) 2007-03-22 2012-10-15 Astrazeneca Ab Derivados de quinolina para el tratamiento de enfermedades inflamatorias
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
US8614326B2 (en) * 2007-08-22 2013-12-24 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
WO2009049791A2 (en) * 2007-10-15 2009-04-23 F. Hoffmann-La Roche Ag Radiolabeled nk3 receptor antagonist
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
EA201170074A1 (ru) * 2008-06-23 2011-10-31 Х. Лундбекк А/С Изохинолиноновые производные в качестве антагонистов nk3
US8242134B2 (en) 2008-09-15 2012-08-14 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
EA201170585A1 (ru) 2008-10-20 2011-12-30 Х. Лундбекк А/С Производные изохинолинона в качестве антагонистов nk3
LT2821400T (lt) 2009-03-20 2018-02-12 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatorių gamybos būdas
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2804859B1 (en) 2012-01-17 2019-06-12 Universiteit Antwerpen Novel fap inhibitors
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
CN102702099A (zh) * 2012-06-21 2012-10-03 江苏恩华药业股份有限公司 (s)-3-羟基-2-苯基-n-(1-苯基丙基)喹啉-4-甲酰胺的制备方法
BR112015026519A2 (pt) 2013-04-19 2017-07-25 Astrazeneca Ab composto antagonista do receptor nk3 (nk3ra) para uso em um método destinado ao tratamento de síndrome do ovário policístico (sop)
WO2015200594A2 (en) 2014-06-25 2015-12-30 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
WO2016004035A1 (en) * 2014-07-01 2016-01-07 Icahn School Of Medicine At Mount Sinai 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases
CN107074773A (zh) 2014-09-09 2017-08-18 拜耳制药股份公司 取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途
ES2702288T3 (es) 2014-10-07 2019-02-28 Vertex Pharma Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
JP2018512404A (ja) 2015-03-18 2018-05-17 バイエル ファーマ アクチエンゲゼルシャフト 置換ｎ−ビシクロ−２−アリール−キノリン−４−カルボキサミドおよびその使用
BR112017024852B1 (pt) * 2015-05-18 2023-10-31 KaNDy Therapeutics Limited Usos de um composto antagonista do receptor nk-1/nk-3 duplo e de uma composição farmacêutica compreendendo dito composto para o tratamento de sintomas vasomotores associados com menopausa
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
WO2017153234A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
WO2017153231A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung
CN105884626B (zh) * 2016-05-04 2017-10-20 龙曦宁（上海）医药科技有限公司 一种2‑氨基茚满衍生物的合成方法及其产品
MX2019012153A (es) * 2017-04-10 2019-11-21 Bayer Ag N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso.
TWI770157B (zh) * 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
EP3704271A4 (en) 2017-11-02 2021-09-08 California Institute of Technology NEUROKININ ANTAGONISTS AND RELATED USES
WO2020101017A1 (ja) * 2018-11-15 2020-05-22 国立大学法人九州大学 Ｉｌ－３１介在性疾患の予防又は治療剤及び医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1560489A (en) * 1976-05-21 1980-02-06 Fisons Ltd Pharmaceutical compositions
FR2538388B1 (fr) 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
DE3905339A1 (de) 1989-02-22 1990-09-06 Basf Ag Chinolin-4-carbonsaeurederivate und deren verwendung
US4992448A (en) * 1989-10-24 1991-02-12 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5037835A (en) * 1989-10-24 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
DE69126058T2 (de) * 1990-03-26 1997-09-25 Matsushita Electric Ind Co Ltd Lichtempfindliches Material für Elektrophotographie
EP0585913B1 (en) * 1992-09-04 1997-12-29 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
RO114445B1 (ro) * 1994-05-27 1999-04-30 Smithkline Beecham S.P.A. Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists

Also Published As

Publication number Publication date
AP9500745A0 (en) 1995-07-31
HK1024469A1 (en) 2000-10-13
ATE273959T1 (de) 2004-09-15
SK4799A3 (en) 1999-06-11
HK1003884A1 (en) 1998-11-13
EP0940391A3 (en) 1999-11-10
TW533199B (en) 2003-05-21
JP2000026314A (ja) 2000-01-25
CN1276211A (zh) 2000-12-13
NO965036L (no) 1997-01-24
SK282721B6 (sk) 2002-11-06
FI990268A0 (fi) 1999-02-10
PL317381A1 (en) 1997-04-01
PT804419E (pt) 2003-12-31
US20030236281A1 (en) 2003-12-25
MA23560A1 (fr) 1995-12-31
JP2007126475A (ja) 2007-05-24
HUT76286A (en) 1997-07-28
HU226535B1 (en) 2009-03-30
HU9603262D0 (en) 1997-01-28
BR9507788A (pt) 1997-09-23
FI119721B (fi) 2009-02-27
JP2005068155A (ja) 2005-03-17
SA95160290A (ar) 2005-12-03
SK282722B6 (sk) 2002-11-06
OA10592A (en) 2002-08-27
EP0940391A2 (en) 1999-09-08
NO991813D0 (no) 1999-04-16
DE69533408D1 (de) 2004-09-23
KR100316571B1 (ko) 2002-05-30
US20050096316A1 (en) 2005-05-05
DE69531458T2 (de) 2004-08-05
WO1995032948A1 (en) 1995-12-07
NO307783B1 (no) 2000-05-29
FI964712A0 (fi) 1996-11-26
ES2227769T3 (es) 2005-04-01
CA2191352A1 (en) 1995-12-07
SA95160290B1 (ar) 2006-06-21
FI990268A (fi) 1999-02-10
NZ287442A (en) 1998-05-27
US5811553A (en) 1998-09-22
CZ291476B6 (cs) 2003-03-12
BG103181A (bg) 1999-09-30
AP578A (en) 1997-03-26
EP0804419B1 (en) 2003-08-06
DE69531458D1 (de) 2003-09-11
ES2204952T3 (es) 2004-05-01
EP0940391B1 (en) 2004-08-18
CZ347096A3 (en) 1997-10-15
JPH10500697A (ja) 1998-01-20
DZ1889A1 (fr) 2002-02-17
FI115052B (fi) 2005-02-28
DK0804419T3 (da) 2003-11-24
JP2002179594A (ja) 2002-06-26
FI964712A (fi) 1997-01-23
US20060160846A1 (en) 2006-07-20
NO326714B1 (no) 2009-02-02
SK151496A3 (en) 1997-07-09
BG101008A (en) 1997-08-29
NO991813L (no) 1997-01-24
JP3664492B2 (ja) 2005-06-29
MY129596A (en) 2007-04-30
NO965036D0 (no) 1996-11-26
RO114445B1 (ro) 1999-04-30
IL113844A0 (en) 1995-08-31
TW427977B (en) 2001-04-01
PL186075B1 (pl) 2003-10-31
PT940391E (pt) 2004-12-31
PL186665B1 (pl) 2004-02-27
DE69533408T2 (de) 2005-09-08
CN1428145A (zh) 2003-07-09
US6608083B1 (en) 2003-08-19
EP0804419A1 (en) 1997-11-05
US7482458B2 (en) 2009-01-27
UA51623C2 (uk) 2002-12-16
AR037069A2 (es) 2004-10-20
CN1092642C (zh) 2002-10-16
CA2191352C (en) 2001-01-30
CN1156451A (zh) 1997-08-06
MX9605903A (es) 1998-08-30
ATE246677T1 (de) 2003-08-15
AU2616495A (en) 1995-12-21
AU699319B2 (en) 1998-12-03
BG64004B1 (bg) 2003-09-30

Similar Documents

Publication Publication Date Title
IL113844A (en) N-(alpha-ETHYLBENZYL)-3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE AND ITS USE IN THE PREPARATION OF MEDICAMENTS
IL116325A0 (en) Substituted 1h-imidazoles their preparation and use
HRP960365B1 (en) New medicaments and the use thereof
IL114795A0 (en) N-benzylindole- and benmzopyrazole derivatives their preparation and use
GB9402706D0 (en) Absorbent materials and preparation thereof
HK1020564A1 (en) Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect
IL125775A0 (en) Use of a zwitterion composition and a pharmaceutical composition containing the same
ZA955781B (en) New chemical compound the preparation thereof and its use in pharmaceutical compositions
GB9219425D0 (en) Therapeutic agent and its use
IL128902A0 (en) N-(2-benzothiazolyl)-1-piperidineethanamine derivatives their preparation and their use in therapy
ZA959904B (en) Iminooxymethyleneanilides thei preparation and their use
IL113415A0 (en) Dihydrodibenzoquinolinediones their preparation and use and pharmaceutical compositions containing them
ZA955128B (en) Novel amido-quinoxalinediones the preparation and use thereof
AU3982695A (en) Oxazolyl- and thiazolylimidazo-benzo- and thienodiazepines and their use as medicaments
ZA911956B (en) 9-chlor-prostaglandin-beta-cyclodextrin-clathrates and their use as medicinal substances
IL116134A0 (en) Iminooxybenzylcrotonate esters their preparation and their use
GB9423267D0 (en) Compounding elements and use thereof
IL118629A0 (en) N-Substituted cis-N-propenyl-acetemides their preparation and use
PH23435A (en) Benzamide and application thereof in the therapeutic field
GB9302553D0 (en) Pharmaceutical preparations and their manufacture and use
IL109356A0 (en) N-substituted-2-azetidinones and their use in the preparation of n-unsubstituted-2-azetidinones
GB9401745D0 (en) Improvements in and relating to the administration of medicaments or therapeutic substances
GB9412618D0 (en) Cytotoxic agent and its use
GB9413076D0 (en) Composition and use
IL114333A0 (en) Pyrimidinyl- and triazinyl-oxy-and-thio-3-haloalkyl-propionic acid derivatives their preparation and use

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees